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In March 2007, a course entitled 
“Immunology and Skin Disease: New 
Perspectives” was given in Boston, 
Massachusetts.* In attendance were 
180 physicians and scientists from 22 
countries. The course, organized by 
Thomas Kupper, Robert Fuhlbrigge, 
and Rachael Clark of the Harvard Skin 
Disease Research Center in Boston, 
covered new developments in the field 
of cutaneous immunology. The key 
findings reported at the meeting are 
summarized here.
The course began with a break-
fast session during which Ulrich von 
Andrian (Harvard University, Boston, 
Massachusetts) presented his studies 
on the imaging of adaptive immune 
responses in skin-draining lymph nodes. 
Using multiphoton microscopy of pop-
liteal lymph nodes in live, anesthetized 
mice, Dr. von Andrian imaged the inter-
actions of T and B cells with antigen-
presenting cells (APCs) and found that 
priming of naive T cells occurs in three 
distinct phases. Using a mouse tumor 
model, he demonstrated that regulatory 
T (T-reg) cells did not block proliferation 
of tumor-specific CD8 cells but did pre-
vent them from degranulating, block-
ing their ability to kill. In vivo imaging 
studies such as these provide the first 
glimpses into T-cell behavior within the 
lymph nodes and other tissues.
Thomas Kupper (Harvard University, 
Boston) outlined the objectives of 
the course and provided a brief intro-
duction to skin immunity, highlight-
ing recent findings by members of the 
Harvard Skin Disease Research Center.
Polly Matzinger (National Institute of 
Allergy and Infectious Diseases (NIAID), 
Bethesda, Maryland) presented updates 
to her danger model of the immune 
response. She discussed a common 
molecular feature of those stimuli that 
are interpreted as danger signals by 
the immune system: hydrophobic por-
tions of molecules (Hyppos). Hyppos 
are normally sequestered within mem-
branes or proteins, and their abrupt 
exposure as a result of injury is inter-
preted as a danger signal. Although the 
receptors on dendritic cells can react to 
microbial nucleic acids and proteins, 
Dr. Matzinger hypothesizes that these 
receptors evolved first to recognize 
endogenous products of cellular injury. 
This puts the injured tissue in control of 
the initiation of an immune response. 
Dr. Matzinger also believes that tis-
sues determine the type of immune 
response to pathogens. As examples, 
she used “privileged sites,” such as the 
eye, where transplants are not rejected. 
Although these sites have been thought 
to be off limits to the immune system, 
it is clear that immunity occurs in 
these tissues, including production of 
protective IgA antibody. The lack of a 
delayed-type hypersensitivity (DTH) 
response, as measured by the failure 
to reject an organ transplant, does not 
mean that there is no immunity at these 
sites but rather that it is switched away 
from potentially destructive DTH reac-
tions toward less destructive classes of 
immunity. Dr. Matzinger proposes that 
DTH (Th1) responses, which are poten-
tially very destructive to tissues, are 
not the default pathway of the immune 
system but are instead employed as a 
last resort to clear pathogens resistant 
to other responses. She suggested that 
each tissue has a default set of instruc-
tions that it communicates to the 
immune system (usually by instruct-
ing local dendritic cells) to ensure that 
a local immune response can clear a 
pathogen without destroying the local 
tissue in the process.
The cutaneous innate immune 
response encompasses many diverse 
elements, ranging from the simple 
barrier function of the skin to more 
complex systems, such as the comple-
ment cascade. Antimicrobial peptides 
(AMPs) are one of the skin’s first lines 
of defense against pathogens. Richard 
Gallo (University of California, San 
Diego) summarized work in this field, 
noting that more than 20 AMPs have 
been identified in skin. These mol-
ecules have varied structures, are 
expressed by many skin cell types, and 
often have multiple biological func-
tions. Dr. Gallo has found that differ-
entially processed forms of the same 
cathelicidin either kill bacteria (the 
shorter form) or serve as pro-inflam-
matory danger signals (the longer 
form). In rosacea, he has found both an 
accumulation of the substrate for cat-
helicidin and an overexpression of the 
enzyme that converts it into the longer, 
pro-inflammatory molecule. The result 
is high production of a long form of 
cathelicidin that leads to inflammation. 
Last, Dr. Gallo discussed his surprising 
finding that cathelicidin production by 
keratinocytes is regulated by vitamin D. 
Wounding or other insults to the skin 
leads to local production of active vita-
min D in keratinocytes, which induces 
cathelicidin production, along with 
upregulation of CD14 and TLR2.
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APCs are another critical element 
of the skin’s innate immune system. 
Dendritic cells (DCs) are particularly 
important because they can stimulate 
naive T cells, thus initiating a primary 
immune response. In addition to stim-
ulation, DCs pass on to T cells addi-
tional information about the nature of 
the pathologic insult and the tissue in 
which it was encountered. These signals 
affect the type of immune response that 
is induced and the expression of tissue-
homing addressins that affect future 
T-cell migration patterns. Mark Udey 
(National Cancer Institute, Bethesda, 
Maryland) summarized recent findings 
in DC biology. Knockout mice deficient 
in Langerhans cells showed that these 
cells are not required for contact sen-
sitivity responses. Models of cutaneous 
leishmaniasis demonstrated the impor-
tant role of IL-12 production in the 
generation of a Th1 response. Severe 
HSV infections in DC-deficient mice 
highlighted the role of DCs in control-
ling this infection. Last, recent work in 
mice suggested that skin-derived APCs 
transport antigen to the draining lymph 
nodes, but, surprisingly, the antigen is 
then handed off to CD8+ lymphoid DCs 
for presentation to T cells. Whether this 
occurs in humans remains to be seen.
Autoimmunity results when the 
immune system mistakenly inter-
prets self antigens as dangerous. Ann 
Marshak-Rothstein (Boston University) 
addressed the role of toll-like recep-
tors (TLRs) in autoimmune disease. She 
observed that targets of autoantigens 
serve as adjuvants by interacting with 
TLRs and triggering B-cell autoimmu-
nity. CpG-rich stretches of mammalian 
(self) DNA are internalized into B cells 
and activate TLR9, leading to prolifera-
tion of these cells and the production 
of autoantibodies. In a similar way, 
mammalian RNA can activate TLR7 
and lead to autoantibody production. 
Dr. Marshak-Rothstein suggested that 
women may be more susceptible to 
autoimmune diseases because the 
TLR7 gene is located on the X chromo-
some and the second copy of this gene 
may be incompletely inactivated by 
lyonization. Thus, increased TLR7 gene 
dosage may lead to an increased risk of 
autoimmunity. Her work highlights the 
important finding that cellular debris 
can activate endogenous TLRs, trig-
gering and maintaining autoimmune 
disease.
NKT cells are thought to recognize 
glycolipid antigens presented by the 
CD1 family of molecules. The role 
of CD1d-restricted NKT cells in the 
immune response was summarized 
by Mark Exley (Harvard University, 
Boston). NKT cells rapidly produce 
large amounts of anti- and/or pro-
inflammatory cytokines and chemo-
kines. The activation of invariant NKT 
cells transiently protects against numer-
ous diseases by stimulating DCs, APCs, 
and other lymphocytes, and these cells 
are needed for optimal responses to 
certain viruses and cancers. Th1-type 
invariant NKT can provide anti-tumor 
immunity, whereas Th2-type noninvari-
ant NKT and T-reg cells can suppress 
anti-tumor responses. In cancer patients 
receiving IL-2 immunotherapy, invari-
ant NKT cells behaved differently from 
other T-cell subsets and were more sim-
ilar to myeloid DC1. Dr. Exley’s work 
suggests that expansion of the invari-
ant NKT cell pool or activation of these 
cells could lead to improved immuno-
therapies for cancer.
T and B cells express antigen-spe-
cific receptors and comprise what is 
termed the adaptive immune system. 
These cells have the ability to respond 
to virtually any antigen and can retain 
memory of past encounters. However, 
getting the right cells to the right place 
at the right time is a logistical chal-
lenge for the immune system. Robert 
Fuhlbrigge (Harvard University, Boston) 
discussed the critical role of cell hom-
ing to this process. He explained that 
tissue-specific “addressins” (adhesion 
molecules and chemotactic factors) 
support the specific and coordinated 
recruitment of cells into particular 
sites at different phases of the immune 
response. For example, T cells that first 
encounter their antigens in skin-drain-
ing lymph nodes develop expression 
of skin addressins, including CLA and 
CCR4, and home preferentially back 
to the skin in the future. Dr. Fuhlbrigge 
has discovered that properly glycosyl-
ated forms of PSGL-1 and CD43 both 
serve as ligands for E-selectin that sup-
port the entry of T cells into the skin 
under both normal and inflamed con-
ditions. He presented evidence for 
an additional, as yet uncharacterized 
E-selectin ligand on human T cells. A 
clearer understanding of the mecha-
nisms of immune surveillance and tis-
sue-specific immune responses in skin 
is critical for the development of novel 
therapeutic agents and more effective 
vaccines.
Frances Lund (Trudeau Institute, 
Saranac Lake, New York) concluded the 
first day of the meeting by presenting 
groundbreaking work demonstrating 
new roles for B cells in inflammatory 
diseases. Antibody production was pre-
viously thought to be the main func-
tion of B cells. However, depletion of 
B cells in patients profoundly reduces 
the clinical symptoms of multiple auto-
immune diseases, despite the con-
tinued presence of autoantibodies. 
Dr. Lund reported new findings that 
mouse B cells can produce an array of 
inflammatory cytokines in response to 
signals provided by T cells and that the 
types of cytokines produced are depen-
dent on the environment in which the 
B cells were initially primed. B cells 
activated by Th1 cells or Th1-type 
pathogens (Be1 cells) made a different 
array of cytokines than B cells activat-
ed by Th2 cells or Th2-type pathogens 
(Be2 cells). In addition, Be1 and Be2 
cells were potent APCs that efficiently 
promoted the development and expan-
sion of effector T cells. T cells primed 
by these biased B cells were in turn 
induced to produce a similar profile of 
inflammatory cytokines. Thus, effector 
B cells can sustain and amplify preex-
isting inflammatory T-cell responses and 
have the potential to exacerbate T-cell-
dependent autoimmunity. Cytokines 
produced by B cells also regulated the 
development and architecture of tertiary 
lymphoid tissues found in autoimmune 
lesions and induced the differentiation 
of B cells into long-lived plasma cells. 
Cytokine-producing B cells are thus 
important regulatory cells that can pro-
foundly influence immune responses 
to pathogens and autoantigens. Last, 
Dr. Lund demonstrated in a mouse 
model of chronic nematode infection 
that B cells regulated the development 
and maintenance of antigen-specific 
CD4+ Th2 cells and produced cytokines 
needed during the effector phase of the 
RA Clark and RC Fuhlbrigge
Immunology and Skin Disease
1840 Journal of Investigative Dermatology (2007), Volume 127
immune response. Together, her findings 
demonstrate that B cells have multiple 
effector functions that are critically 
important during immune responses 
to pathogens and likely play a role in 
autoimmunity as well.
The second day of the conference 
began with a lively discussion by Arlene 
Sharpe (Harvard University, Boston) of 
the role that molecules in the B7:CD28 
family play in T-cell activation and tole-
rance. The B7:CD28 family of recep-
tors can either inhibit or enhance T-cell 
responses. Dr. Sharpe generated knock-
out mice deficient in the expression 
of PD-L1 and PD-L2, ligands for the 
recently characterized costimulatory 
molecule PD-1. She reported that islet 
cells express PD-1 and that nonobese 
diabetic mice develop accelerated dia-
betes in the absence of PD-1 ligands. 
Protection was restored when PD-L1 
was expressed by the tissues but not by 
immune cells, suggesting that PD-L1 
expression by tissues may shield them 
from autoimmune attack. Additional 
work suggests that microorganisms may 
also utilize the PD-1 pathway to escape 
host immunity, allowing for chronic 
infection.
Skin resident T cells—the T cells 
that reside within noninflamed human 
skin—play a critical role in providing 
immunosurveillance of the skin, con-
tribute to psoriasis, and likely play a 
role in other inflammatory skin disor-
ders as well. Rachael Clark (Harvard 
University, Boston) presented her work 
on the isolation and study of these cells. 
She has found that normal-appearing 
human skin is populated by 1 million 
memory T cells/cm2, suggesting that 
there are nearly twice as many T cells 
in normal skin than are present in the 
entire circulation. These cells express 
the skin homing addressins CLA and 
CCR4, indicating that homing to both 
normal and inflamed skin probably 
occurs via similar mechanisms. Dr. 
Clark has discovered that human skin 
also contains a population of FOXP3+ 
T-reg cells. These cells expand under 
conditions similar to those in inflamed 
skin, suggesting that local proliferation 
of T-reg cells within the skin may serve 
as a brake for cutaneous inflammation. 
Last, Dr. Clark described her recent 
work characterizing the mechanisms 
by which squamous cell carcinomas 
(SCCs) of the skin evade the immune 
system. She found evidence that SCCs 
evade the immune response by stealth 
and by suppression, subverting the nor-
mal processes of tissue-specific T-cell 
homing and tolerance induction to 
remain undetected by the immune sys-
tem.
Regulatory T cells play a crucial role 
in the establishment and maintenance 
of self-tolerance. Ethan Shevac (NIAID, 
Bethesda, Maryland) reported that 
transfer of polyclonal FOXP3+ T-reg cells 
into mice blocked the development of 
autoimmune gastritis. T-reg cells did 
not block proliferation of specific effec-
tor T cells but blocked their differentia-
tion into pathogenic Th1-type effector 
cells. He found that TCR stimulation of 
mouse T cells in the presence of TGF-β 
induced FOXP3 expression, giving rise 
to induced T-reg cells that suppressed 
gastritis. These induced T-reg cells 
decreased the ability of DCs to present 
antigen, at least in part by downregu-
lating expression of CD80 and CD86. 
Dr. Shevac has also observed FOXP3 
expression in human T cells stimulated 
by TCR ligation and TGF-β but deter-
mined that these cells have no suppres-
sive ability. He discussed the technical 
difficulties of working with T-reg cells, 
including the inadequacy of magnetic 
beads for isolating T-reg cells and differ-
ences in FOXP3 antibodies. His work 
suggests a role for FOXP3+ T-reg cells 
in modifying the ability of autoreactive 
DCs to present antigen to pathogenic 
T cells.
Many inflammatory skin diseases are 
caused or exacerbated by T-cell activa-
tion and proliferation within the skin. 
The activation of T cells by APCs with-
in the skin is central to understanding 
both normal immunity and the altera-
tions of this process that give rise to 
inflammatory skin diseases. Stephan 
Grabbe (University of Essen, Germany) 
discussed his studies of the role that 
integrins play in DC–T-cell interactions. 
Within collagen gels, T cells and DCs 
form an immunologic synapse, induc-
ing cytoskeletal remodeling within the 
DCs, which is required for full T-cell 
activation. Surprisingly, the β2 integrins 
are not required for antigen presenta-
tion and DCs from normal mice express 
inactive β2 integrins. Artificial activa-
tion of β2 integrins with Mg2+ actually 
impairs DC activation of T cells, an 
effect mediated by Mac-1 (CD11b/
CD18) on DC. Blockade of Mac-1 also 
increases macrophage activation of 
T cells. Dr. Grabbe observed that Mac-
1 is known to bind to cellular debris 
and hypothesized that inactivation 
of Mac-1 in professional APCs may 
serve to protect against presentation of 
autoantigens and may thus protect 
against autoimmunity.
An understanding of DC physiology is 
also central to the development of more 
effective vaccines. Akira Takashima 
(University of Toledo, Ohio) reported the 
identification of novel DC stimulatory 
compounds by use of a high-throughput 
screening assay. Dr. Takashima has dis-
covered that two common medications, 
colchicine and podophyllotoxin, have 
potent and previously unsuspected abili-
ties to activate DCs. Findings from this 
work may lead to the development of a 
new class of DC-targeted vaccine adju-
vants and immunostimulants.
The last segment of the conference 
focused on discussion of specific skin 
diseases, including graft-versus-host dis-
ease (GvHD), psoriasis, atopic dermati-
tis (AD), and cutaneous lymphomas. 
Some truly groundbreaking work was 
presented that emphasized the impor-
tance of dendritic cells in determining 
the host response.
James Krueger (Rockefeller 
University, New York) presented work 
that suggested a key role for TNF- and 
iNOS-producing dendritic cells in pso-
riasis. Dr. Krueger reported that these 
cells are key producers of IL-23 and 
IL-10, cytokines that stimulate Th17 
T cells to produce IL-17 and IL-22. These 
cytokines in turn produce alterations in 
epidermal keratinocytes, leading to pso-
riasiform hyperplasia. One additional 
key observation made by Dr. Krueger 
was that psoriasis and AD share a great 
number of susceptibility genes, and the 
genes that differ between these disor-
ders are those expressed by DCs. This 
suggests that a common set of genes 
predisposes individuals to the develop-
ment of both disorders and whether a 
person develops psoriasis or AD may 
depend on the characteristics of his or 
her dendritic cells.
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Thomas Bieber (University of Bonn, 
Germany) presented his groundbreak-
ing and eminently useful research on 
AD. He reported that the earliest stages 
of AD in infants begin as a dermatitis 
lacking IgE-mediated specific immu-
nity. This, together with an altered skin 
barrier, allows the immune system to 
become sensitized to environmental 
allergens, leading to skin inflamma-
tion and IgE-mediated allergy. Chronic 
itching and scratching then leads to 
a third phase of the disease, in which 
sensitivity to self proteins, or “autoal-
lergens,” sets up a patient for long-term 
AD that is actually a form of autoreac-
tivity. Dr. Bieber also noted that cal-
cineurin inhibitors may change the 
phenotype and function of epider-
mal DCs in AD, perhaps leading to 
resurgence in Langerhans cell-medi-
ated tolerance within the skin. His work 
highlights the fact that a decrease in 
the skin’s barrier function can set up 
patients for lifelong sensitization to both 
environmental and self antigens. His 
results suggest that good skin care and 
emollients, together with anti-inflam-
matory topical medications, not only 
improve symptoms but also may help 
stop the progression of allergic disease.
Paul Nghiem (University of 
Washington, Seattle) reviewed cur-
rent knowledge about the diagnosis 
and management of GvHD. It can be 
very difficult to distinguish between 
drug eruptions and GvHD in transplant 
recipients, yet the treatments for these 
two problems are markedly different 
and untreated GvHD can be rapidly 
fatal. A recent decision analysis showed 
that, for populations of patients with a 
prior probability of GvHD of at least 
30%, the best approach is to treat pre-
sumptively for GvHD and forgo a skin 
biopsy altogether. Skin biopsies simply 
cannot distinguish between the two 
conditions. Dr. Nghiem also reviewed 
recent findings suggesting that T-reg 
cells may be capable of attenuating or 
preventing GvHD after hematopoietic 
stem cell transplant. The number of 
 T-reg cells in the blood falls with devel-
opment of GvHD, and extracorporeal 
photopheresis, which increase the num-
bers of T-reg cells, is effective in treating 
the condition. Photopheresis may work 
by producing apoptotic debris that, 
when phagocytosed by DCs, induces 
them to adopt a tolerogenic phenotype. 
These tolerogenic DCs may then induce 
the formation of T-reg cells.
The final session was a thought-
provoking discussion of cutaneous T-cell 
lymphoma (CTCL) by Madeleine Duvic 
(University of Texas, Houston). CTCL 
remains a somewhat enigmatic group 
of malignancies, and many hypoth-
eses have been put forth to explain 
the underlying physiology. Malignant 
T cells in CTCL have defective apop-
tosis that may allow them to accumu-
late within skin lesions. It may be that 
chronic antigen stimulation drives the 
proliferation of T cells that eventually 
develop genetic mutations, giving rise 
to the malignant clones that character-
ize later stages of disease. Dr. Duvic 
has demonstrated colonization of CTCL 
patients with superantigen-producing 
Staphylococcus aureus and expansion 
of superantigen-reactive T cells in these 
patients. The role of T-reg cells in CTCL 
is controversial. It has been suggested 
that CTCL is a malignancy of T-reg cells, 
yet photopheresis, which increases the 
number of these cells, is effective in 
the treatment of the disease. A deeper 
understanding of CTCL awaits the 
development of a unifying hypothesis 
capable of explaining the many confus-
ing aspects of this group of diseases.
The course was then concluded by 
Dr. Kupper with thanks to the organiz-
ers, speakers, and attendees. The course 
will be held again in two years, on a 
date to be announced.
*Immunology and Skin Disease: 
New Perspectives was held at the 
Fairmont Copley Plaza Hotel in Boston, 
Massachusetts, USA, 22–24 March 2007.
